2:56 PM
 | 
Jan 09, 2019
 |  BC Extra  |  Company News

Elevian, AI company Insilico partner to find anti-aging candidates in GDF11 pathway

Elevian Inc. (Allston, Mass.) partnered with AI company Insilico Medicine Inc. (Baltimore, Md.) to use deep-learning technology to discover small molecules that target the GDF11 pathway to treat age-related diseases.

Insilico will apply its generative adversarial networks and reinforcement learning technologies to biological and structural target data from Elevian to identify small molecules that produce the intended biological actions. Insilico will then narrow down a selection of de novo compound candidates, which will be synthesized by WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359). Financial terms were not disclosed.

GDF11, part of the TGFβ family, affects cellular growth and development; and GDF deficiency in mice causes developmental abnormalities, such as agenesis of the kidneys and perinatal lethality.

Elevian, a Harvard University spinout that emerged from stealth in September, is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company aims to modulate the protein’s pathway with antibodies, small molecules or recombinant versions of the protein itself (see "GDF11 Against Aging").

In August, Insilico partnered with Juvenescence Ltd. (Douglas, Isle of Man) and the Buck Institute for Research on Aging (Novato, Calif.) to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands), which will use Insilico's deep learning platform to discover small molecules against an undisclosed aging-related target (see "Juvenescence, Partners Form Anti-Aging Biotech").

GDF11 - Growth differentiation factor 11; TGFβ - Transforming growth factor β

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD